Current Report Filing (8-k)
July 22 2021 - 05:19PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 19, 2021
LIFEMD,
INC.
(Exact
name of Registrant as specified in its charter)
Delaware
|
|
001-39785
|
|
76-0238453
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
800
Third Avenue, Suite 2800
New
York, NY 10022
(Address
of principal executive offices, including zip code)
(866)
351-5907
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:
[ ]
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.01 per share
|
|
LFMD
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Chief
Acquisition Officer Compensation
Effective
July 19, 2021, LifeMD, Inc. (the “Company”) and Nicholas Alvarez, its Chief Acquisition Officer, entered into the First Amendment
(the “Amendment”) to the Amended and Restated Employment Agreement dated December 8, 2020 (the “Agreement”) between
the Company and Mr. Alvarez to (i) increase Mr. Alvarez’s base salary from $172,400 to $300,000 per year, (ii) specify that the
discretionary Performance Bonus (as defined in the Amendment) may be up to $125,000 and (iii) change the governing law of the Agreement
to New York.
Item
5.02 of this Current Report on Form 8-K contains only a brief description of the material terms of the Amendment and does not purport
to be a complete description of the rights and obligations of the parties to the Amendment, and such description is qualified in its
entirety by reference to the full text of the Amendment, which is attached as Exhibit 10.1 to this current report on Form 8-K and is
incorporated herein by reference.
Item
9.01 Exhibits
(d)
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
LIFEMD,
INC.
|
|
|
|
|
Dated: July 22, 2021
|
By:
|
/s/
Justin Schreiber
|
|
|
|
Justin
Schreiber
|
|
|
|
Chief
Executive Officer
|
LifeMD (NASDAQ:LFMD)
Historical Stock Chart
From Feb 2024 to Mar 2024
LifeMD (NASDAQ:LFMD)
Historical Stock Chart
From Mar 2023 to Mar 2024